Incyte Corporation
1801 Augustine Cut-Off
Wilmington
Delaware
19803
United States
673 articles about Incyte Corporation
-
Incyte to Present at Upcoming Investor Conference - Feb 03, 2022
2/3/2022
Incyte announced that it will present at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 11:20 a.m. ET.
-
Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis
1/28/2022
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) today announced updates on the Phase 3 development program for OLUMIANT ® (baricitinib) in adults with active systemic lupus erythematosus (also referred to as SLE and lupus) and the status of the U.S. atopic dermatitis supplemental new drug application (sNDA).
-
Eli Lilly and Company announced that it was discontinuing the Phase III development program for Olumiant (baricitinib) in lupus.
-
Incyte's decision follows consultation with the FDA, where it decided that it could not support any confirmatory studies that might be required in the future given the limited time frame.
-
Incyte Provides Update on Parsaclisib and MCLA-145
1/25/2022
Incyte (Nasdaq:INCY) today announced updates regarding the clinical development of parsaclisib, the Company’s next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ), and MCLA-145, its CD137/PD-L1 bispecific antibody co-developed under a global collaboration and license agreement with Merus.
-
Incyte to Report Fourth Quarter and Year-End 2021 Financial Results
1/18/2022
Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2021 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 8, 2022.
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
Researchers from the Medical University of Bialystok in Poland identified a gene that appears to double the risk of severe COVID-19.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura™) as a Treatment for Patients with Vitiligo
12/14/2021
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for ruxolitinib cream 1.5% (Opzelura™) a topical JAK inhibitor, as a potential treatment for adolescents and adults (age ≥12 years) with vitiligo.
-
Incyte to Present at Upcoming Investor Conferences in January 2022
12/14/2021
Incyte announced that it will present at the following investor conferences during the month of January.
-
Incyte Announces Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
12/11/2021
Incyte announced data from three ongoing Phase 2 studies evaluating parsaclisib, an investigational novel potent, highly selective, next-generation oral inhibitor of phosphatidylinositol 3-kinase delta, for the treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma .
-
Incyte to Present at Upcoming Investor Conference - Nov 09, 2021
11/9/2021
Incyte announced that it will present at the Evercore ISI 4th Annual HealthCONx Conference on Tuesday, November 30, 2021 at 2:15 p.m. ET.
-
More than 35 Abstracts from Incyte’s Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition
11/4/2021
Incyte announced that numerous abstracts highlighting data from its oncology portfolio will be presented at the upcoming 63rd American Society of Hematology Annual Meeting and Exposition, held December 11–14, 2021 in Atlanta, Georgia and virtually.
-
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
11/2/2021
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
-
Data from Incyte’s Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
11/1/2021
Incyte announced that multiple abstracts highlighting data from its oncology portfolio will be presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting, held from November 10-14, 2021 in Washington, D.C and virtually.
-
Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas
11/1/2021
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for parsaclisib, an investigational novel potent, highly selective, next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ)
-
Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in Vitiligo
10/28/2021
Incyte (Nasdaq:INCY) today announced the validation of the European Marketing Authorization Application (MAA) for ruxolitinib cream
-
Incyte to Report Third Quarter 2021 Financial Results
10/13/2021
Incyte announced that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, November 2, 2021.